Company Overview and News

to your dashboard

Headline News

Selectin Inhibition Justifies GlycoMimetics Investment

2017-11-15 seekingalpha
GlycoMimetics has partnered with Pfizer examining lead candidate Rivipansel, a pan selectin inhibitor, in VOC-associated SCA phase 3 trials. (26-0)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good morning. And thank you all for joining GlycoMimetics Third Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a brief question-and-answer session. And at that time, the lines will be opened for you. [Operator Instructions] (20-0)

ROTY Edition 1 Volume 48: Cutting A Position Loose And Promising Updates On Current Holdings

2017-11-08 seekingalpha
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)

ROTY Volume 1 Edition 45: More Trades And Updates

2017-11-02 seekingalpha
I finally cut a "loser" from the ROTY model account. While the fundamental thesis appears on track, I can`t ignore the weak technicals any longer. (68-1)

Why Earnings Season Could Be Great for GlycoMimetics (GLYC)

2017-11-02 zacks
Investors are always looking for stocks that are poised to beat at earnings season and GlycoMimetics, Inc. (GLYC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (55-0)

GlycoMimetics: ASH Update

2017-11-02 seekingalpha
I reiterate that while GlycoMimetics's shelf offering might have caused weakness in the share price, comparisons to Celator lead me to believe the stock is heavily undervalued. (263-1)

GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting | Business Wire

2017-11-01 businesswire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that data related to its lead clinical candidate, GMI-1271, will be highlighted in two oral presentations at the 59th American Society of Hematology (ASH) Annual Meeting and Expo. The ASH meeting will take place in Atlanta, GA, December 9-12, 2017. (20-1)

Paper: GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

2017-11-01 ash.confex
Daniel J. DeAngelo, MD, PhD1, Brian A Jonas, MD, PhD2, Jane L. Liesveld, MD3, Dale L. Bixby4*, Anjali S. Advani, MD5, Paula Marlton, MBBS6, Michael O'Dwyer, MD7, John L Magnani, PhD8, Helen M. Thackray, MD8 and Pamela S. Becker, MD, PhD9 (45-0)

ROTY Volume 1 Edition 42: Thoughts On Underpeformers And New Trades

2017-10-24 seekingalpha
We are also swapping a Contender for a current ROTY holding due to higher perceived upside and an important near term catalyst. (132-6)

GlycoMimetics: Buy The Dip

2017-10-23 seekingalpha
A recently filed $250 million mixed securities shelf offering could also have scared investors into thinking that further dilution is ahead. (23-0)

4 Biotech Stocks Worth Buying A Pullback In

2017-10-16 seekingalpha
Weakness in several big winners of 2017 could be providing a chance to initiate or add to a position. (55-0)

ROTY Volume 1 Edition 39: Tracking Performance And How To React To Weakness

2017-10-14 seekingalpha
Readers have requested a performance tracker and so it will appear going forward in each edition. (452-5)

The Small Cap Rush!

2017-10-10 seekingalpha
The enduring power of small cap relative outperformance presents a compelling investment case for long-term investors. (267-1)

Glycomimetics Is An Exceptional Investment Opportunity Both For Short-Term And Long-Term

2017-10-09 seekingalpha
I first heard of GLYC from StockMatusow's research back in May 2017. StockMatusow did a fabulous job explaining the company, science, and potential of the Company as an investment. I was very intrigued by the story and have remained as a shareholder for about 5 months. Though I have always been a bullish investor of GLYC for its long-term outlook, I think now is an interesting time to add/start a position in GLYC. (20-2)

CUSIP: 38000Q102